180 related articles for article (PubMed ID: 27764830)
41. A case report of malignant neuroectodermal tumor of the gastrointestinal tract without common gene fusion in a soft tissue tumor.
Liu ZL; Zhou B; Zhao YJ; Yu MQ; Liang J; Li Y
J Gastrointest Oncol; 2022 Jun; 13(3):1489-1498. PubMed ID: 35837202
[TBL] [Abstract][Full Text] [Related]
42. ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.
Ahn HK; Han B; Lee SJ; Lim T; Sun JM; Ahn JS; Ahn MJ; Park K
Lung Cancer; 2012 May; 76(2):253-4. PubMed ID: 22385925
[TBL] [Abstract][Full Text] [Related]
43. A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors.
Henary H; George GC; Wheler J; Naing A; Piha-Paul S; Fu S; Mistry R; Zinner R; Kurzrock R; Hong DS
Cancer Chemother Pharmacol; 2015 Sep; 76(3):597-603. PubMed ID: 26210681
[TBL] [Abstract][Full Text] [Related]
44. Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanoma.
Allanson BM; Weber MA; Jackett LA; Chan C; Lau L; Ziegler DS; Warby M; Mayoh C; Cowley MJ; Tucker KM; Long GV; Maher A; Anazodo A; Scolyer RA
Pathology; 2018 Oct; 50(6):648-653. PubMed ID: 30177220
[TBL] [Abstract][Full Text] [Related]
45. Long-lasting response to third-line crizotinib treatment in a patient with non-small cell lung cancer with brain metastases and poor performance status.
Li DL; Chen XR; Ma SX; Chen LK
Thorac Cancer; 2016 Sep; 7(5):619-622. PubMed ID: 27766783
[TBL] [Abstract][Full Text] [Related]
46. Primary subcutaneous spindle cell Ewing sarcoma with strong S100 expression and EWSR1-FLI1 fusion: a case report.
Arnold MA; Ballester LY; Pack SD; Abdullaev Z; Merchant M; Tsokos MG
Pediatr Dev Pathol; 2014; 17(4):302-7. PubMed ID: 24735198
[TBL] [Abstract][Full Text] [Related]
47. Malignant Gastrointestinal Neuroectodermal Tumor of Small Intestine Showing DOG1 Expression: A Case Report and Review of Literature.
Shalaby A; Telugu RB; Deshpande PA; Qureshi A; Al Adawi H; Al Harthi S; Al Hinai K; Al Miskry H; Nadaf A; Niaz Z; Al Riyami M; Itkin B; Al Haddabi IH
Int J Surg Pathol; 2024 Apr; 32(2):374-379. PubMed ID: 37248556
[TBL] [Abstract][Full Text] [Related]
48. Expression and clinical relevance of MET and ALK in Ewing sarcomas.
Fleuren ED; Roeffen MH; Leenders WP; Flucke UE; Vlenterie M; Schreuder HW; Boerman OC; van der Graaf WT; Versleijen-Jonkers YM
Int J Cancer; 2013 Jul; 133(2):427-36. PubMed ID: 23335077
[TBL] [Abstract][Full Text] [Related]
49. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
Cappuzzo F; Moro-Sibilot D; Gautschi O; Boleti E; Felip E; Groen HJ; Germonpré P; Meldgaard P; Arriola E; Steele N; Fox J; Schnell P; Engelsberg A; Wolf J
Lung Cancer; 2015 Feb; 87(2):89-95. PubMed ID: 25576294
[TBL] [Abstract][Full Text] [Related]
50. EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer.
Wang Y; Zhang J; Gao G; Li X; Zhao C; He Y; Su C; Zhang S; Chen X; Zhang J; Li W; Li B; Zhao J; Hou L; Wu C; Ren S; Zhou C; Zhang J
J Thorac Oncol; 2015 Nov; 10(11):1546-52. PubMed ID: 26352533
[TBL] [Abstract][Full Text] [Related]
51. Crizotinib administered via nasogastric and percutaneous endoscopic gastrostomy tubes for the successful treatment of ALK-rearranged lung cancer in a patient with poor performance status.
Tamai K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Katakami N; Tomii K
Respir Investig; 2013 Mar; 51(1):46-8. PubMed ID: 23561259
[TBL] [Abstract][Full Text] [Related]
52. Primary malignant neuroectodermal tumor of the ileum with predominantly uncommon pseudopapillary architecture.
Zhao Z; Zhang D; Li W; Zhang L; Li Z; Zhou J
Int J Clin Exp Pathol; 2014; 7(12):8967-71. PubMed ID: 25674274
[TBL] [Abstract][Full Text] [Related]
53. In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line.
Nanjo S; Nakagawa T; Takeuchi S; Kita K; Fukuda K; Nakada M; Uehara H; Nishihara H; Hara E; Uramoto H; Tanaka F; Yano S
Cancer Sci; 2015 Mar; 106(3):244-52. PubMed ID: 25581823
[TBL] [Abstract][Full Text] [Related]
54. Crizotinib reduces the rate of dark adaptation in the rat retina independent of ALK inhibition.
Liu CN; Mathialagan N; Lappin P; Fortner J; Somps C; Seitis G; Johnson TR; Hu W; Matsumoto D
Toxicol Sci; 2015 Jan; 143(1):116-25. PubMed ID: 25326243
[TBL] [Abstract][Full Text] [Related]
55. Efficacy and safety of crizotinib among Chinese EML4-ALK-positive, advanced-stage non-small cell lung cancer patients.
Cao Y; Xiao G; Qiu X; Ye S; Lin T
PLoS One; 2014; 9(12):e114008. PubMed ID: 25501361
[TBL] [Abstract][Full Text] [Related]
56. Crizotinib for the treatment of patients with advanced non-small cell lung cancer.
Bowles DW; Weickhardt AJ; Doebele RC; Camidge DR; Jimeno A
Drugs Today (Barc); 2012 Apr; 48(4):271-82. PubMed ID: 22536569
[TBL] [Abstract][Full Text] [Related]
57. Primary pulmonary myxoid sarcoma with EWSR1-CREB1 fusion, resembling extraskeletal myxoid chondrosarcoma: Case report with a review of Literature.
Matsukuma S; Hisaoka M; Obara K; Kono T; Takeo H; Sato K; Hata Y
Pathol Int; 2012 Dec; 62(12):817-22. PubMed ID: 23252871
[TBL] [Abstract][Full Text] [Related]
58. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.
Gambacorti Passerini C; Farina F; Stasia A; Redaelli S; Ceccon M; Mologni L; Messa C; Guerra L; Giudici G; Sala E; Mussolin L; Deeren D; King MH; Steurer M; Ordemann R; Cohen AM; Grube M; Bernard L; Chiriano G; Antolini L; Piazza R
J Natl Cancer Inst; 2014 Feb; 106(2):djt378. PubMed ID: 24491302
[TBL] [Abstract][Full Text] [Related]
59. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
60. Malignant gastrointestinal neuroectodermal tumor (clear cell sarcoma-like tumor of the gastrointestinal tract) of the small intestine in a 12-year-old boy.
Wolak P; Wincewicz A; Czauderna P; Spałek M; Kruczak A; Urbaniak-Wąsik S; Ryś J; Michalak E; Woltanowska M; Sulkowski S
Dev Period Med; 2018; 22(4):358-363. PubMed ID: 30636233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
